AMGN Stock Recent News
AMGN LATEST HEADLINES
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m.
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious complication of powerful chemotherapy cancer drugs, researchers reported ahead of the American Society of Clinical Oncology meeting in Chicago.
Amgen (AMGN -0.36%) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13 times forward earnings estimates compared to 21 for the S&P 500.
TROY, Mich. , May 27, 2025 /PRNewswire/ -- Stride Inc.'s recent report has investors wondering if the company's stock is overvalued.
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
The stock market is anything but normal right now. Not even halfway through the year, the broader benchmark S&P 500 index fell nearly 20% from highs made in February, only to make a full recovery for the year (as of May 22).
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again.
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companies seem to have somewhat promising prospects in this field.